Cook Jennifer E. — SEC Form 4 filings
SEC reporting owner CIK 1754371. 13 Form 4 filings on record with FilingPulse; latest filed 2026-09-02.
Transaction summary — filings shown
Covers all 13 filings on record, filed 2024-06-04 to 2026-09-02. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 7 legs across 4 filings — 279,650 shares, $21,952,117 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 32.
- Largest priced transaction: sale of 112,422 shares @ $90.00 ($10,117,980) in BridgeBio Pharma, Inc., filed 2026-07-13.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | Director | 5 | — | 6 legs · 278,192 sh · $21,920,435 | 19 |
| Denali Therapeutics Inc. (DNLI) | Director | 4 | — | 1 leg · 1,458 sh · $31,682 | 6 |
| Jazz Pharmaceuticals plc (JAZZ) | Director | 4 | — | — | 7 |
Form 4 filings — Cook Jennifer E.
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-02 | 4 | Jazz Pharmaceuticals plc (JAZZ) | Tax withholding (F): 14 @ $244.06 · Tax withholding (F): 1,692 @ $241.39 | EDGAR |
| 2026-08-07 | 4 | Jazz Pharmaceuticals plc (JAZZ) | Grant/award (A): 1,605 @ $0 | EDGAR |
| 2026-07-13 | 4 | BridgeBio Pharma, Inc. (BBIO) | Option exercise (M): 19,000 @ $8.45 · Option exercise (M): 112,422 @ $29 · Option exercise (M): 17,167 @ $16.75 · Sale (S): 36,167 @ $84 · Sale (S): 112,422 @ $90 · Option exercise (M): 19,000 (derivative) @ $0 · +2 more | EDGAR |
| 2026-06-24 | 4 | BridgeBio Pharma, Inc. (BBIO) | Grant/award (A): 3,990 @ $0 · Sale (S): 2,196 @ $68.57 · Option exercise (M): 20,000 @ $8.45 · Option exercise (M): 17,167 @ $16.75 · Sale (S): 37,167 @ $70 · Grant/award (A): 5,277 (derivative) @ $0 · +2 more | EDGAR |
| 2026-06-17 | 4 | BridgeBio Pharma, Inc. (BBIO) | Option exercise (M): 65,921 @ $8.45 · Option exercise (M): 17,167 @ $16.75 · Sale (S): 88,737 @ $66.62 · Sale (S): 1,503 @ $67.14 · Option exercise (M): 65,921 (derivative) @ $0 · Option exercise (M): 17,167 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | Denali Therapeutics Inc. (DNLI) | Grant/award (A): 6,408 @ $0 · Grant/award (A): 19,226 (derivative) @ $0 | EDGAR |
| 2025-08-11 | 4 | Jazz Pharmaceuticals plc (JAZZ) | Grant/award (A): 3,507 @ $0 · Tax withholding (F): 1,805 @ $111.25 | EDGAR |
| 2025-06-24 | 4 | BridgeBio Pharma, Inc. (BBIO) | Grant/award (A): 6,589 @ $0 · Grant/award (A): 8,425 (derivative) @ $0 | EDGAR |
| 2025-06-05 | 4 | Denali Therapeutics Inc. (DNLI) | Grant/award (A): 6,037 @ $0 · Grant/award (A): 18,111 (derivative) @ $0 | EDGAR |
| 2024-08-06 | 4 | Jazz Pharmaceuticals plc (JAZZ) | Grant/award (A): 3,731 @ $0 · Tax withholding (F): 1,484 @ $111.35 | EDGAR |
| 2024-06-25 | 4 | BridgeBio Pharma, Inc. (BBIO) | Grant/award (A): 26,014 (derivative) @ $0 | EDGAR |
| 2024-06-10 | 4 | Denali Therapeutics Inc. (DNLI) | Sale (S): 1,458 @ $21.73 | EDGAR |
| 2024-06-04 | 4 | Denali Therapeutics Inc. (DNLI) | Grant/award (A): 5,967 @ $0 · Grant/award (A): 17,901 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1754371 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →